Santen Acquires Eyevance Pharmaceuticals for $225M

Advancing Eyecare Acquires Santinelli International

January 5, 2022

Medical Devices

Advancing Eyecare, a portfolio company of Atlantic Street Capital, has acquired Santinelli International, a long‑standing provider of optical finishing and lens edging equipment. The acquisition expands Advancing Eyecare's product portfolio and service capabilities in the ophthalmic equipment market and integrates Santinelli's edgers, blockers, tracers, consumables and accessories into the platform.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Incyte Acquires Escient Pharmaceuticals

April 23, 2024

Biotechnology

Incyte has agreed to acquire Escient Pharmaceuticals for $750 million plus Escient's net cash, adding two first‑in‑class oral MRGPR antagonists (EP262 and EP547) to its inflammation and autoimmunity portfolio. The acquisition, subject to customary closing conditions and HSR clearance, expands Incyte's pipeline in dermatology, chronic urticaria and pruritus with expected closing in 3Q 2024.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva, Inc. agreed to acquire all outstanding shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis' equity at approximately $113 million on a fully diluted basis. The transaction makes Entasis a wholly owned subsidiary of Innoviva and advances Innoviva's strategy to expand into differentiated late-stage biopharmaceutical assets, including Entasis' lead antibacterial candidate SUL-DUR.

Avesi Partners Invests in Visante

February 12, 2024

Healthcare Services

Avesi Partners has made a minority growth investment in Visante, a St. Paul–based provider of tech-enabled pharmacy consulting and services for health systems. The partnership will support Visante’s growth and capability expansion across specialty and infusion pharmacy markets and includes an internal leadership transition with Steve Rough named CEO and Jim Jorgenson moving to an advisory role.

Astellas Acquires IVERIC bio for Approximately $5.9 Billion

April 29, 2023

Biotechnology

Astellas Pharma has agreed to acquire 100% of IVERIC bio for $40.00 per share, implying an aggregate equity value of roughly $5.9 billion. The acquisition strengthens Astellas' ophthalmology capabilities and adds Iveric's lead program avacincaptad pegol (ACP) for geographic atrophy secondary to AMD to Astellas' pipeline.